Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study
Epistemonikos ID: 4fbd9ebd5677cf28fc69fd371a2b76d88a519869
First added on: May 07, 2024